100 results about "Anticoagulant" patented technology

The invention relates to the technical field of intelligent materials, in particular to low-temperature-resistant magnetorheological fluid and a preparation method thereof.The low-temperature-resistant magnetorheological fluid is prepared from, by weight, 60-75 parts of magnetic particles; 3 to 15 parts of modified magnetic particles; 10-25 parts of low-temperature-based carrier liquid, which comprises 40-60% of silicone oil and / or mineral oil, 20-30% of synthetic ester and 10-20% of poly-alpha-olefin; 0.1 to 1.0 part of a dispersant; 0.5 to 2.0 parts of an anticoagulant; wherein the modified magnetic particles are prepared by coating magnetic particles with SiO2 aerogel and grafting the coated magnetic particles with fluorine-containing silane; the preparation method comprises the steps that magnetic particles are sequentially subjected to silane coupling agent treatment, aerogel deposition and fluorine-containing silane gas-phase grafting, and modified magnetic particles are prepared; carrying out ultrasonic mixing on the base carrier liquid and an anticoagulant at 40-60 DEG C for 30 minutes; adding magnetic particles, modified magnetic particles and a dispersing agent, dispersing by adopting a micro-jet homogenizer, and then carrying out gradient cooling treatment. The low-temperature-resistant magnetorheological fluid has the effect of improving the low-temperature-resistant performance of the magnetorheological fluid.

The invention belongs to the technical field of blood detection, and particularly relates to an experimental animal blood detection device which comprises a detector body and a sample injection needle, and further comprises a sample mixing part, and the sample mixing part comprises a disc rotationally installed on the detector body; the fixing bases are installed on the disc, and clamping assemblies are rotationally installed on the fixing bases; the driving assembly is installed on the fixing base and comprises a main shaft rotationally installed on the fixing base and an auxiliary shaft used for driving the clamping jaw to rotate, a plurality of sets of auxiliary gears and main gears are installed on the auxiliary shaft and the main shaft respectively, the tooth ratios of the auxiliary gears and the main gears in each set are different, and the auxiliary shaft is of a telescopic structure; by arranging the driving assembly, different shaking speeds are adopted for blood collection tubes of different specifications, it is ensured that blood and an anticoagulant are evenly mixed, the situation of hemolysis or uneven mixing is avoided, and the detection accuracy and efficiency are improved.

The invention discloses cattle whole blood collection equipment, relates to the technical field of cattle whole blood collection, and aims to solve the technical problems that the proportion of an anticoagulant and blood is difficult to control, the collection efficiency and quality are low, and the blood is easy to coagulate, and the sample loss risk is increased in the current collection equipment. After the blood drip cup is connected to the bovine blood collection equipment, the collected bovine blood is conveyed to one end of the mixing assembly through the peristaltic pump, the anticoagulant is conveyed to the other end of the mixing assembly through the anticoagulant tube according to the preset proportion and flow through the other peristaltic pump, the blood and the anticoagulant are fully converged and fused in the mixing assembly, and the blood collection efficiency is improved. The bovine whole blood can be rapidly and uniformly mixed together, the blood coagulation tendency is inhibited, and it is ensured that the collected bovine whole blood keeps good fluidity and activity in the follow-up treatment and storage process. The cattle whole blood collection efficiency and quality are improved, and the sample loss and experimental error risks caused by blood coagulation are reduced.

The invention discloses an extraction method of leech anticoagulant protein, and belongs to the technical field of biological extraction.According to the extraction method, after components of induction liquid are optimized, mucous membranes are activated, and the living tissue environment naturally sucked by leeches is simulated, so that the leeches can be induced to better suck, the sucking amount of the leeches is guaranteed, and the anti-coagulation protein content of the leeches is improved; the leeches can be effectively stimulated to secrete more anticoagulant proteins with higher activity; meanwhile, under the coordination effect of the tranquilizer, the leech is kept in a warm state, so that the silent and relaxed physiological state of the leech can still be ensured in a dizziness stimulation or air pressure difference stimulation state, the loss of the living leech can be reduced, conditions for repeated extraction are provided for the leech, the gland secretion activity of the leech tends to be stable and vigorous, and the survival rate of the leech is increased. The extraction rate is further improved.

The invention relates to the field of medical instruments, in particular to a composite heparin anticoagulant coating and a preparation method thereof. The method comprises the following steps: ultraviolet light pretreatment: carrying out ultraviolet light pretreatment on a substrate material to initiate polyethyleneimine to be grafted on the surface of the material; turning coating: coating the surface of the substrate material with a heparin solution, and fixing with an EDC solution; and the coating direction is changed in the coating process. Amino chains are introduced to the surface of a substrate material through ultraviolet light, the surface is provided with positive charges, and the heparin coating is formed through ionic bond combination. After the coating is completed, the coating is fixed by using an EDC solution, and the coating direction is changed in the coating process, so that the stability, the uniformity, the hydrophilicity and the anticoagulation performance of the coating are improved.

The invention discloses an anticoagulation endothelium slow release promoting coating and a preparation method thereof, and relates to the technical field of biomedical materials, the method comprises the following steps: soaking a substrate material in a guide layer solution prepared from dopamine, a silane coupling agent containing double bonds and an amino compound; immersing in an assembly layer solution prepared from a double-bond functionalized high-molecular compound and an endothelial active promoting substance, taking out, and carrying out photo-crosslinking curing; and immersing in a regulation and control layer solution prepared from a double-bond functionalized high-molecular compound and a zwitterionic monomer, and finally taking out for photo-crosslinking and curing to obtain the anti-coagulation endothelial sustained-release promoting coating. According to the method, efficient packaging and slow release of anticoagulation and endothelialization promoting active substances are achieved, and the prepared coating remarkably improves the performance of a blood contact instrument in the aspects of acute-stage thrombus formation resistance and long-acting endothelialization promotion after implantation.

The utility model provides a prefilled anticoagulant temporary storage device which comprises a barrel body and opening and closing strips, a top cover is detachably arranged on the top of the barrel body, an installation block is arranged on the top of the top cover, a plurality of containing pipes are vertically arranged on the installation block in a penetrating mode, each containing pipe is communicated with the barrel body, and the opening and closing strips correspond to the containing pipes one to one. Each opening and closing strip is horizontally and slidably arranged on the mounting block in a penetrating mode, a strip-shaped groove allowing the opening and closing strip to be inserted is formed in the side wall of each containing pipe, and the problem that in the prior art, when medical staff recheck the type and dosage of the pre-filled anticoagulant, the risk that the medical staff are punctured by a needle head exists is solved.

The invention relates to a blood contact material and a preparation method thereof. The preparation method of the blood contact material comprises the following steps that the anticoagulant layer is covalently connected to the surface of the base material in an atom transfer radical polymerization mode, the tail end of a polymer in the anticoagulant layer is provided with an initiator group, and the anticoagulant layer comprises one or more of a hydrophilic anticoagulant layer and a heparin anticoagulant layer; and reacting the initiator group with the substance with the NO catalytic release function to prepare the blood contact material. According to the preparation method, the stability of the membrane layer can be improved while a relatively good antithrombotic effect is ensured.

Provided herein are novel methods, compositions, and kits for targeting antithrombotic (LTAT) molecules using lymph. The LTAT molecule can be used for treating or preventing lymphatic thrombosis caused by infection or inflammation, in particular in the intestinal tract.

The utility model relates to the technical field of medical instruments, in particular to a blood sampling test tube placing rack for outpatient nursing, which comprises a fixing frame, a rotating shaft, a placing frame, a small motor and the like. The left side and the right side of the top of the fixing frame are rotationally connected with at least three rotating shafts, a placing frame is connected between the left rotating shaft and the right rotating shaft, each placing frame is provided with at least five inserting holes allowing test tubes to be inserted, a small motor is installed on one side of the fixing frame, and an output shaft of the small motor is fixedly connected with the rotating shaft in the middle. Due to the arrangement of the placing frames, the rotating shaft, the transmission belt and the small motor, the placing frames rotate along the rotating shaft under the transmission action of the transmission belt, so that blood and an anticoagulant in a test tube are fully mixed, the effectiveness of blood sampling is ensured, manual shaking up is not needed, the mixing efficiency of the blood and the anticoagulant is improved, time can be saved, and the working efficiency is improved. And a fixing block, a clamping block and a connecting spring are further arranged, so that the clamping block can be clamped and fixed, and the test tube is prevented from being thrown out of the placing frame during rotation.

The invention belongs to the technical field of biology, and relates to an anticoagulant fusion protein HSA-Qinghaenin (c), a coding gene and application thereof, in particular to preparation of the anticoagulant fusion protein and application of the anticoagulant fusion protein in the fields of prevention of in-vivo thrombus formation and preparation of anticoagulant coating biological materials. Compared with an existing anticoagulant coating, the material surface anticoagulant coating based on the anticoagulant fusion protein HSA-Qinghaenin (c), provided by the invention, shows remarkable advantages. Through self-polymerization of polydopamine, the adhesiveness of the coating and a substrate material is greatly improved, and the stability and durability of the coating are ensured. HSA in the anticoagulant fusion protein HSA-Qinghaenin (c) can inhibit the adsorption of plasma proteins and platelets, the Qinghaenin (c) takes FXII in an endogenous blood coagulation pathway as a target spot, the activation of a blood coagulation factor is inhibited, meanwhile, the risk of inducing bleeding is avoided, and the HSA-Qinghaenin (c) can play a role of'one stone and two birds' in the aspect of anticoagulation of a biological material.

The present invention provides an anticoagulant reversal agent which is a compound having the structure represented by formula I, a salt thereof, or a deuterated thereof. Experimental results have shown that the compound according to the present invention can more effectively suppress hemorrhagic complications caused by anticoagulants such as warfarin, heparin, and enoxaparin sodium, and exhibits high efficacy over a broad spectrum.

Provided is a medicinal liquid supply device which is less constrained by a packaging material of a medicinal liquid such as heparin, and is capable of being used for multiple rounds of treatment using the medicinal liquid on a package by package basis. A medicinal liquid supply device is for supplying a medicinal liquid to a blood circuit included in a blood purification device for purifying blood, and comprises: a composition-holding part into which an anticoagulant housed in a container can be introduced from the container, and which holds a composition containing at least the introduced anticoagulant; and a linking part that links the composition-holding part to the blood circuit, and allows the composition to be guided out from the composition-holding part to the blood circuit.

The invention discloses a blood routine microsphere, a preparation method thereof and application of the blood routine microsphere in a vacuum blood collection tube, and belongs to the technical field of medical instruments. The blood routine microsphere is composed of ethylenediamine tetraacetic acid salt and an excipient, all the components are dissolved in deionized water to form a solution, the solution is rapidly frozen in liquid nitrogen through a bead dropping machine to form a microsphere precursor, and then the freeze-dried microsphere with the diameter of 2.0-6.0 mm is prepared through a vacuum freeze-drying process. The microspheres have the characteristics of uniform particle size, rapid dissolution and stable anticoagulation effect. The microspheres are applied to a vacuum blood collection tube. According to the invention, the production process of the traditional vacuum blood collection tube is simplified, the defects that the liquid anticoagulant is not uniformly sprayed and blood coagulation is easily caused are overcome, the product quality and the production efficiency are improved, and the production cost is reduced.

The invention relates to the field of medical health and intelligent optimization, and discloses a dialysis anticoagulation risk intelligent early warning method and system fused with multi-modal physiological signals, and the method comprises the steps: S1, synchronously collecting the multi-modal data of a patient in the dialysis process, and standardizing the multi-modal data into a unified time sequence matrix; s2, inputting the unified time sequence matrix into an anticoagulation risk prediction model, performing first-class feature extraction on continuous monitoring signals, performing second-class feature extraction on discrete detection signals, and extracting embedding features of patient individualization and treatment scene data; performing cross-modal fusion on the three types of extracted features to generate a fusion feature vector, and outputting a thrombus risk probability and a bleeding risk probability in a future preset time period; s3, when the risk probability exceeds the corresponding early warning threshold value, performing search optimization on the administration parameter of the current anticoagulant, and generating a dose adjustment instruction; and S4, executing the adjustment instruction, predicting the anti-coagulation risk again, and evaluating the regulation and control effect. Therefore, the safety and effectiveness of the hemodialysis process are remarkably improved.

The invention relates to the technical field of biomedical materials, in particular to an anticoagulation hemodialysis membrane, a base material of the anticoagulation hemodialysis membrane is polysulfone or polyethersulfone, the anticoagulation hemodialysis membrane is of a porous asymmetric structure, and the inner wall surface, making contact with blood, of the hemodialysis membrane is of a bionic micro-nano composite structure. The structure comprises micron-sized bulges and nano-sized particles distributed on the surfaces of the micron-sized bulges, a zwitterionic polymer is covalently grafted on the surface of the micro-nano composite structure and the inner wall of a membrane pore channel; heparin molecules are covalently bonded to the tail end of the zwitterionic polymer. According to the anticoagulant hemodialysis membrane, the anticoagulant performance is qualitatively improved while the excellent mechanical strength, solute clearance rate and ultrafiltration performance of a traditional polysulfone membrane are kept.

The invention relates to the technical field of medical instruments, in particular to a heparin coating based on material surface ammonification modification and a preparation method thereof, and the preparation method at least comprises the following steps: carrying out ultrasonic pretreatment on a base material with purified water, and drying for later use; the preparation method comprises the following steps: performing amination modification on a base material subjected to ultrasonic pretreatment by adopting an ammoniation reagent solution, and immersing the base material into a heparin solution to prepare the base material with a heparin coating on the surface. The surface of the material is subjected to amination modification by adopting a micromolecular ammoniation reagent and / or a macromolecular ammoniation reagent system, complex pretreatment such as plasma and ultraviolet rays does not need to be carried out on a base material, specific functional group activation does not need to be carried out on heparin, and the heparin is directly reacted after being subjected to ammoniation modification; the stable covalent grafted heparin anticoagulation coating can be formed, the anticoagulation time is prolonged, and the long-term implantation requirement is met.

The invention relates to a composition for hematology analyses and to the method for producing same. The composition comprises an anticoagulant, in an amount of between 0.1% and 8% by weight, preferably between 2% and 6%; a salt in an amount of between 30% and 90% by weight, preferably between 50% and 80%; a pH buffer in an amount of between 0.1% and 50% by weight, preferably greater than or equal to 10%; and a surfactant in an amount of between 0.01% and 2% by weight, preferably between 0.05% and 1.5%, in solid form. The invention also relates to a solution obtained from the solid composition.

The invention belongs to biomedical materials, and particularly relates to an anticoagulant coating material for a blood contact material and application of the anticoagulant coating material. The anticoagulant coating material comprises a bottom coating material and a top coating material which are independently packaged; the bottom layer coating material is prepared by crosslinking an amino compound and a silane coupling agent, the amino compound and the silane coupling agent are subjected to a grafting reaction, and the bottom layer coating material contains an uncrosslinked amino compound; the top coating material comprises a bionic hydrophilic anticoagulant and a reducing agent, and the bionic hydrophilic anticoagulant is a phosphate compound. An anticoagulant coating formed on the surface of a blood contact material by the anticoagulant coating material provided by the invention has excellent hydrophilic performance and relatively low dynamic and static hemolysis rates, which shows that the anticoagulant coating material has excellent anticoagulant performance.

The utility model relates to the technical field of medical instruments, in particular to an EDTA (Ethylene Diamine Tetraacetic Acid) anticoagulation tube which comprises a tube body and a tube cover screwed at the open end of the tube body, a buckle is arranged on the outer wall of the pipe cover, a convex ring is formed at the open end of the pipe body, and the buckle is clamped with the convex ring after the pipe cover is in threaded connection with the pipe body, so that the pipe cover is limited to be separated from the pipe body in the axial direction of the pipe body; an anticoagulant is added into the tube body; according to the anti-freezing tube, the tube cover buckle and the tube body convex ring form axial limiting clamping connection, a double-locking mechanism is formed by matching threaded connection, even if threads are slightly loosened, the buckle can still prevent the tube cover from being separated from the tube body, and the problem of sample leakage caused by loose threaded connection of a traditional anti-freezing tube is fundamentally solved; and the safety of the blood sample in the collection, transportation and storage processes is ensured.

The invention discloses a portable hemodialysis instrument capable of preventing a loop from being blocked, and relates to the technical field of hemodialysis instruments. The blood pumping device comprises a shell, a reciprocating driving mechanism is arranged in the shell, a piston film is fixedly installed in a loop cavity in the shell, the reciprocating driving mechanism drives the piston film to reciprocate for blood pumping operation, and a sealing cover is fixedly installed at the end of the shell. According to the device, blood enters extracorporeal circulation through the connecting end, the flow monitoring mechanism monitors the blood flow of the blood inlet end and the blood return end in real time, when it is detected that the flow of the blood inlet end is obviously lower than the flow of the blood return end, it is indicated that thrombus is possibly formed or blockage is likely to happen in a loop, and at the moment, the anti-coagulation and anti-blocking mechanism is immediately started; the blood inlet pipeline is accurately filled with anticoagulant, initial thrombus is actively dissolved, and blockage expansion is prevented, so that manual shutdown cleaning in the background technology is avoided, dialysis continuity and safety are guaranteed, and one-way flowing of blood is guaranteed through the one-way valves on the two connecting ends.

The invention discloses a method for efficiently detecting trace residues of'three-high 'drugs in fish plasma, the'three-high' drugs comprise triamterene, terazosin, rosiglitazone, lovastatin, benazepril, pitavastatin and repaglinide, and the method comprises the following steps: adding an anticoagulant into a collected fish plasma sample, centrifuging, taking supernate, and collecting the supernate; the method comprises the following steps: firstly, adding an internal standard solution, adding acetone containing formic acid with the volume fraction of 1% into a purification tube, loading a labeled sample, pressurizing to ensure that the sample drips in a drop shape, collecting by using a polypropylene test tube containing a purification reagent, oscillating and purifying, centrifuging, taking supernate, and concentrating to obtain a concentrated solution; the method disclosed by the invention is high in sensitivity, and the detection limit range of seven kinds of drugs for target'three highs' in the blood plasma of the aquatic environment fish is 0.02-0.25 ng / mL.

A pharmaceutical composition comprising glutathione disulfide or pharmaceutically acceptable organic or inorganic salts thereof and glutathione disulfide S-oxide of the structure (I) or pharmaceutically acceptable organic or inorganic salts thereof for eliminating dose-related toxicity of pharmacologically active compounds and enhancing therapeutic activity of pharmacologically active compounds in the treatment of infectious and non-infectious diseases. Typically, the composition contains 0.01-10% of glutathione disulfide S-oxide by weight of the total composition, in addition to a metal (Me) in the form of a complexing compound containing Me-S-glutathione bond, said metal being selected from platinum group elements, typically platinum. The amount of d-metal complexing compound administered to a patient can be 10 ‑3 to 10 ‑15 mol / kg of body weight. The composition can be used in combination with pharmacologically active compounds, which are anticoagulants, factor Xa inhibitors, antibacterial or antiviral agents, to increase their therapeutic activity and eliminate dose-related toxicity.

This invention relates to the field of in vitro culture and antigen preparation technology, and discloses an antibiotic-free culture medium and a method for preparing autologous whole blood antigen. The culture medium is a liquid culture medium with a pH of 7.2-7.4, composed of a basic nutrient system, an activation and stimulation system, a stable anticoagulant system, and a virus and bacteria support system, with the remainder being water for injection. This invention constructs a composite culture system comprising a basic nutrient system, an activation and stimulation system, a stable anticoagulant system, and a virus and bacteria support system, enabling the culture medium to simultaneously meet the survival and activation needs of endogenous microorganisms and immune cells within the same system. It achieves synergistic support for both biological systems, thereby completing the culture process without separating whole blood components, and providing a stable environment for obtaining autologous whole blood antigen.

The utility model relates to the technical field of medical instruments, in particular to centrifugal equipment for preparing PRP. The centrifugal equipment comprises a refrigerating device, a centrifugal device and an auxiliary cooling module, a first cooling space and a second cooling space which are adjacently arranged are formed in the refrigerating device, the first cooling space provides a low-temperature environment for the centrifugal device, and the refrigerating device and the centrifugal device are combined to cool the centrifugal device. The PRP prepared by the centrifugal device can be kept at a low temperature to avoid solidification and deterioration of the PRP, use of an anticoagulant is avoided, the use effect of the PRP is improved, meanwhile, the auxiliary cooling module is arranged in the second cooling space adjacent to the first cooling space, when the centrifugal device is used for repeatedly opening and closing the cover body to take blood, temperature rise in the first cooling space is avoided, and the service life of the PRP is prolonged. And the low-speed low-temperature centrifugal machine only needs to open the cover body and put the blood reagent tube into the centrifugal device, so that the low-speed low-temperature centrifugal machine is simple and convenient to operate and convenient for clinical application.

The invention discloses an animal epidemic disease sampling detection device, and relates to the technical field of animal epidemic disease detection, the animal epidemic disease sampling detection device comprises a box body and a box cover hinged on the box body, a sealing plate is arranged in the box body, the sealing plate divides the box body into an activity chamber and a heat preservation chamber, a test tube storage rack is arranged in the box body, and the test tube storage rack is located in the heat preservation chamber; the test tube storage rack comprises a placement plate, a bottom plate, a vertical rod, two test tube fixing assemblies and a transmission mechanism used for driving the test tube fixing assemblies to rotate. Through cooperation of the transmission mechanism and the test tube fixing assembly, all test tubes can uniformly and stably rotate, sample blood and an anticoagulant can be fully mixed, and in the rotation process of the test tubes, the outer walls of the test tubes and constant-temperature gas in the heat preservation chamber are subjected to heat exchange, so that the stability of the test tubes is improved. It is ensured that the blood sample in the test tube is maintained within a proper temperature range, blood sample deterioration or detection result deviation caused by temperature changes is avoided, and the accuracy and reliability of the detection result are ensured.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Various methods, apparatuses, and systems are provided for detecting a genetic disorder in a gene associated with a nuclease, for determining an efficacy of a dosage of an anticoagulant, and for monitoring an activity of a nuclease. Measured parameter values can be compared to a reference value to determine classifications of a genetic disorder, efficiency, or activity. An amount of a particular base (e.g., in an end motif) at fragment ends, an amount of a particular base at fragment ends of a particular size, or a total amount of cell-free DNA fragments (e.g., as a concentration) can be used. Certain samples may be treated with an anticoagulant, and different incubation times can be used for certain methods.